July 3rd 2024
Tycel Phillips, MD, discusses the evolution of treatment with BTK inhibitors for patients with mantle cell lymphoma.
June 6th 2024
Tycel Phillips, MD, MPH, discusses updated efficacy and safety data with glofitamab for the treatment of relapsed/refractory mantle cell lymphoma.
March 28th 2024
Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.
March 7th 2024
Tycel Phillips, MD, discusses efforts to clarify and refine the treatment paradigm of patients with mantle cell lymphoma.
March 5th 2024
Tycel Phillips, MD, discusses unmet needs for patients with relapsed/refractory mantle cell lymphoma.
March 1st 2024
Tycel Phillips, MD, discusses the landscape of treatment for patients with mantle cell.
January 17th 2024
Tycel Phillips, MD, discusses the potential advantages of treating patients with relapsed/refractory mantle cell lymphoma in the phase 3 GLOBRYTE trial.
October 4th 2023
Tycel Phillips, MD, discusses current and emerging therapeutic treatment strategies for patients with mantle cell lymphoma.
August 31st 2023
Tycel Phillips, MD, MPH, discusses the ongoing phase 3 ECHO trial of acalabrutinib plus bendamustine and rituximab in the front line for patients with mantle cell lymphoma.
June 20th 2023
Tycel Phillips, MD, MPH, discusses the updated safety profile and clinical activity seen with the addition of acalabrutinib to bendamustine and rituximab in patients with mantle cell lymphoma.
June 7th 2023
Tycel Phillips, MD, MPH, discusses the safety and efficacy of acalabrutinib plus bendamustine and rituximab from a phase 1 trial in patients with treatment-naive and relapsed/refractory mantle cell lymphoma.
May 23rd 2023
Tycel Phillips, MD, MPH, discusses the implications of the FDA approval of pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.
May 22nd 2023
Tycel Phillips, MD, MPH, discusses treatment options for patients with relapsed/refractory mantle cell lymphoma who have progressed on covalent BTK inhibitors.
May 19th 2023
Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
February 13th 2023
Tycel Phillips, MD, MPH, discusses the key implications of investigating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma.
January 27th 2023
Tycel Phillips, MD, discusses the significance of the FDA approval of pirtobrutinib in mantle cell lymphoma.
December 11th 2022
Tycel Phillips, MD, MPH, discusses the investigation of glofitamab monotherapy in relapsed/refractory mantle cell lymphoma.